Brellium

Name: Brellium
Brand: Brellium
Rating: 4.8 (13 reviews)

AI Native

Brellium is a healthcare software platform that reviews clinical documentation, checks compliance, and supports medical coding before billing alongside an organization’s existing EHR.

Est 2021|29 Ref Customers

LinkedIn 6K|Website|FTEs 73

Published Oct 15, 2026

01Common complaints

Small-volume practices with weak economics: The historical 500-patient/month example demonstrates a plausible non-purchase case. Obtain a scoped quote and compare net savings with manual or outsourced review.
Organizations mainly seeking faster note writing: Evaluate a documentation-first product such as Eleos rather than assuming an auditing layer will solve that problem.
Organizations mainly seeking touchless multispecialty coding: Compare Fathom and CodaMetrix against the exact specialties, code sets, automation thresholds, and EHR workflow required. Brellium’s most detailed public stories concern auditing.
Buyers needing unrestricted overseas residency or dedicated single tenancy: Those options were not publicly established; the disclosed architecture is US-hosted and multi-tenant.
Teams unable to fund calibration and correction work: Rula’s rollout shows that findings require trained staff and ongoing validation.
Buyers expecting unconditional clawback coverage: The published limitations described above materially affect the protection’s value.
Buyers requiring a self-serve trial before commitment: Capterra lists no free trial; the vendor publicly offers a demo. Ask whether a paid or negotiated pilot is available and what its acceptance criteria are.
Calibration-related incorrect feedback: A vendor-identified Reddit response acknowledges that inaccurate findings can occur during calibration; older customer complaints provide examples. Current prevalence is unknown.
Integration breadth versus workflow depth: Brellium claims 60+ EMR integrations, but this does not establish uniform bidirectional synchronization or embedded correction workflows.
API documentation: A customer story establishes API use, but public rate limits, versioning guarantees, webhook behavior, and supported writeback fields were not obtained.
Scale limits: No independently validated maximum chart volume, organization size, or performance breakpoint was found. The anonymous larger-company warning is insufficient to quantify one.
Security evidence freshness: Updated assurance reports and testing dates remain a procurement requirement, as discussed above.
Coverage and outcome gaps: Public stories do not establish clinical-event sensitivity, denial reductions, coding accuracy by specialty, or measured patient-health improvement.
Roadmap: CortexLM was announced October 13, 2026. Specialty and revenue-cycle expansion were described, but public delivery dates, release criteria, and generally available scope were not established.

Overall assessment: Brellium merits a controlled evaluation for organizations with substantial documentation-review needs and the staff to calibrate and act on findings. The public evidence supports operational usefulness more strongly than independently verified financial protection, clinical outcomes, or autonomous-coding accuracy. A purchase decision should turn on a locally measured pilot, integration proof, and negotiated commercial protections—not aggregate marketing metrics.

- **Small-volume practices with weak economics:** The historical 500-patient/month example demonstrates a plausible non-purchase case. Obtain a scoped quote and compare net savings with manual or outsourced review. - **Organizations mainly seeking faster note writing:** Evaluate a documentation-first product such as Eleos rather than assuming an auditing layer will solve that problem. - **Organizations mainly seeking touchless multispecialty coding:** Compare Fathom and CodaMetrix against the exact specialties, code sets, automation thresholds, and EHR workflow required. Brellium’s most detailed public stories concern auditing. - **Buyers needing unrestricted overseas residency or dedicated single tenancy:** Those options were not publicly established; the disclosed architecture is US-hosted and multi-tenant. - **Teams unable to fund calibration and correction work:** Rula’s rollout shows that findings require trained staff and ongoing validation. - **Buyers expecting unconditional clawback coverage:** The published limitations described above materially affect the protection’s value. - **Buyers requiring a self-serve trial before commitment:** Capterra lists no free trial; the vendor publicly offers a demo. Ask whether a paid or negotiated pilot is available and what its acceptance criteria are. - **Calibration-related incorrect feedback:** A vendor-identified Reddit response acknowledges that inaccurate findings can occur during calibration; older customer complaints provide examples. Current prevalence is unknown. - **Integration breadth versus workflow depth:** Brellium claims 60+ EMR integrations, but this does not establish uniform bidirectional synchronization or embedded correction workflows. - **API documentation:** A customer story establishes API use, but public rate limits, versioning guarantees, webhook behavior, and supported writeback fields were not obtained. - **Scale limits:** No independently validated maximum chart volume, organization size, or performance breakpoint was found. The anonymous larger-company warning is insufficient to quantify one. - **Security evidence freshness:** Updated assurance reports and testing dates remain a procurement requirement, as discussed above. - **Coverage and outcome gaps:** Public stories do not establish clinical-event sensitivity, denial reductions, coding accuracy by specialty, or measured patient-health improvement. - **Roadmap:** CortexLM was announced October 13, 2026. Specialty and revenue-cycle expansion were described, but public delivery dates, release criteria, and generally available scope were not established. **Overall assessment:** Brellium merits a controlled evaluation for organizations with substantial documentation-review needs and the staff to calibrate and act on findings. The public evidence supports operational usefulness more strongly than independently verified financial protection, clinical outcomes, or autonomous-coding accuracy. A purchase decision should turn on a locally measured pilot, integration proof, and negotiated commercial protections—not aggregate marketing metrics.

02Why they buy

Configurable clinical-quality auditing: Customer evidence supports tailoring rubrics to organization-specific documentation standards. This is a specific capability, rather than a general claim about AI use.
Broad review coverage without proportional manual reading: Customer stories and favorable reviews support the operational appeal of reviewing substantially more notes. Independent system-wide error-detection effectiveness remains unproven.
Provider-level improvement workflows: Rula’s story links flags to coaching and template improvement rather than merely producing an audit report.
Customer-specific integration flexibility: Rula describes API collaboration and additional endpoints. This does not establish that equivalent integration is standard for every EHR.

No feature was established as categorically unavailable from all competitors. Eleos also offers comprehensive scanning, while coding-first competitors offer more explicitly documented coding workflows. Brellium’s differentiation is best viewed as its combination of clinical auditing, customization, and operational support—not exclusive ownership of full-chart AI review.

- **Configurable clinical-quality auditing:** Customer evidence supports tailoring rubrics to organization-specific documentation standards. This is a specific capability, rather than a general claim about AI use. - **Broad review coverage without proportional manual reading:** Customer stories and favorable reviews support the operational appeal of reviewing substantially more notes. Independent system-wide error-detection effectiveness remains unproven. - **Provider-level improvement workflows:** Rula’s story links flags to coaching and template improvement rather than merely producing an audit report. - **Customer-specific integration flexibility:** Rula describes API collaboration and additional endpoints. This does not establish that equivalent integration is standard for every EHR. No feature was established as categorically unavailable from all competitors. Eleos also offers comprehensive scanning, while coding-first competitors offer more explicitly documented coding workflows. Brellium’s differentiation is best viewed as its combination of clinical auditing, customization, and operational support—not exclusive ownership of full-chart AI review.

03Field reports

Review availability and evidence quality

Capterra: Highly rated on Capterra with a small review footprint.
Software Advice: Predominantly five-star and four-star ratings, with no lower-star ratings reported.
GetApp: Shows several five-star and a few four-star reviews; overlapping content suggests these should not be treated as independent customer populations.
G2: The Brellium seller page lists no reviews. Search results for similarly named, unrelated products were excluded.
Gartner Peer Insights: No Brellium review page was established; the reviews endpoint was inaccessible to automated access.
TrustRadius: Searches did not locate usable Brellium-specific customer reviews.
Hacker News: No relevant Brellium discussion was found.

Accordingly, a true comparison between high-star and low-star review populations cannot be supplied. There were no accessible low-star product reviews to quote. Negative Reddit experiences and criticisms embedded within otherwise favorable reviews are presented instead, without assigning invented ratings.

- **Capterra:** Highly rated on Capterra with a small review footprint. - **Software Advice:** Predominantly five-star and four-star ratings, with no lower-star ratings reported. - **GetApp:** Shows several five-star and a few four-star reviews; overlapping content suggests these should not be treated as independent customer populations. - **G2:** The Brellium seller page lists no reviews. Search results for similarly named, unrelated products were excluded. - **Gartner Peer Insights:** No Brellium review page was established; the reviews endpoint was inaccessible to automated access. - **TrustRadius:** Searches did not locate usable Brellium-specific customer reviews. - **Hacker News:** No relevant Brellium discussion was found. Accordingly, a true comparison between high-star and low-star review populations cannot be supplied. There were no accessible low-star product reviews to quote. Negative Reddit experiences and criticisms embedded within otherwise favorable reviews are presented instead, without assigning invented ratings.

Positive feedback

David, president; positive Capterra review: “Intuitive interface, extremely customizable, and excellent customer support.” This is a favorable assessment after several months of use, not a controlled productivity measurement.
Kelsey A., VP Operations; favorable review: Reported that audit costs were halved and praised responsive, customized implementation support. No baseline costing or independent validation was supplied.
Reddit, r/ABA: “Requires a lot of training and fine tuning initially.” The same commenter said the product removed substantial work from a compliance manager and was considered worthwhile. The commenter did not know the price.

- **David, president; positive Capterra review:** “Intuitive interface, extremely customizable, and excellent customer support.” This is a favorable assessment after several months of use, not a controlled productivity measurement. - **Kelsey A., VP Operations; favorable review:** Reported that audit costs were halved and praised responsive, customized implementation support. No baseline costing or independent validation was supplied. - **Reddit, r/ABA:** “Requires a lot of training and fine tuning initially.” The same commenter said the product removed substantial work from a compliance manager and was considered worthwhile. The commenter did not know the price.

Negative and mixed feedback

Peter M., VP Finance; positive Capterra review: “No integrated workflow with our health record system.” Despite praising large-scale note review, this customer identified an operational integration gap.
Heather, AR Manager; mixed review: “Interface can be difficult to navigate.” The review also criticized the cost of additional audits while praising customer service.
Reddit, r/ABA: “It likes to tell me I recorded 0 goals during my session. Oh and that I used an ‘insufficient’ amount of sentences.” The complaint concerns apparently incorrect or overly mechanical feedback. The original uses double quotation marks around “insufficient.”
Vendor response: An account identifying itself as CEO Zach Rosen acknowledged that such behavior sometimes occurs, particularly during implementation calibration, and offered assistance. Identity was not independently authenticated.
Reddit: A commenter claiming direct experience advised against Brellium for larger companies. No organization size, failure mechanism, or supporting evidence was supplied; this is a low-confidence warning, not proof of a scale ceiling.

- **Peter M., VP Finance; positive Capterra review:** “No integrated workflow with our health record system.” Despite praising large-scale note review, this customer identified an operational integration gap. - **Heather, AR Manager; mixed review:** “Interface can be difficult to navigate.” The review also criticized the cost of additional audits while praising customer service. - **Reddit, r/ABA:** “It likes to tell me I recorded 0 goals during my session. Oh and that I used an ‘insufficient’ amount of sentences.” The complaint concerns apparently incorrect or overly mechanical feedback. The original uses double quotation marks around “insufficient.” - **Vendor response:** An account identifying itself as CEO Zach Rosen acknowledged that such behavior sometimes occurs, particularly during implementation calibration, and offered assistance. Identity was not independently authenticated. - **Reddit:** A commenter claiming direct experience advised against Brellium for larger companies. No organization size, failure mechanism, or supporting evidence was supplied; this is a low-confidence warning, not proof of a scale ceiling.

Selection, non-purchase, and churn

Non-purchase evidence is more concrete than churn evidence: one small-practice buyer rejected the ROI, while another resisted a lengthy, expensive commitment and perceived signing pressure. No named, independently verified customer departure to a specific competitor was established.

Rula’s vendor-published story says it chose Brellium over building internally to preserve engineering capacity and obtain a configurable solution. Public reviews also emphasize reviewing more notes without hiring a proportionately larger audit team. Non-purchase evidence is more concrete than churn evidence: one small-practice buyer rejected the ROI, while another resisted a lengthy, expensive commitment and perceived signing pressure. No named, independently verified customer departure to a specific competitor was established.

Headspace

Starting problem: Periodic manual review covered only a fraction of clinical documentation.
Workflow: Custom clinical audit questions check documentation supporting therapy add-on codes, medication monitoring, and contraindication-related issues.
Published result: Very high provider compliance with specified documentation standards; a vendor announcement describes therapy-note coverage increasing from minimal to complete.
Critical evaluation: The result is not model accuracy, payer acceptance, or improved patient outcomes. Sample size, measurement interval, denominator, independent adjudication, and a numeric baseline compliance rate are not disclosed. Deployment duration and total cost are also absent.

This is a named, vendor-published customer story, not independent confirmation of the complete deployment scope or claimed outcomes.

- **Starting problem:** Periodic manual review covered only a fraction of clinical documentation. - **Workflow:** Custom clinical audit questions check documentation supporting therapy add-on codes, medication monitoring, and contraindication-related issues. - **Published result:** Very high provider compliance with specified documentation standards; a vendor announcement describes therapy-note coverage increasing from minimal to complete. - **Critical evaluation:** The result is not model accuracy, payer acceptance, or improved patient outcomes. Sample size, measurement interval, denominator, independent adjudication, and a numeric baseline compliance rate are not disclosed. Deployment duration and total cost are also absent. This is a named, vendor-published customer story, not independent confirmation of the complete deployment scope or claimed outcomes.

Lightfully Behavioral Health

Starting problem: The Director of Clinical Quality reportedly faced a substantial weekly time burden managing chart audits.
Published result: A substantially reduced chart-review time, with all charts audited across levels of care.
Operational interpretation: Applied to a comparable baseline, the reported reduction would imply only a small remaining weekly time commitment. This is arithmetic, not an additional observed result.
Critical evaluation: The short story provides no measurement period, chart-volume adjustment, implementation timeline, license cost, false-positive rate, or total provider correction time. Savings for the audit manager may not equal organization-wide labor savings.

The supplied homepage quotation adds customer attribution, but independent verification was not found.

- **Starting problem:** The Director of Clinical Quality reportedly faced a substantial weekly time burden managing chart audits. - **Published result:** A substantially reduced chart-review time, with all charts audited across levels of care. - **Operational interpretation:** Applied to a comparable baseline, the reported reduction would imply only a small remaining weekly time commitment. This is arithmetic, not an additional observed result. - **Critical evaluation:** The short story provides no measurement period, chart-volume adjustment, implementation timeline, license cost, false-positive rate, or total provider correction time. Savings for the audit manager may not equal organization-wide labor savings. The supplied homepage quotation adds customer attribution, but independent verification was not found.

Rula

Starting problem: Manual sampling and reviewer inconsistency limited visibility into note quality.
Implementation: Clinicians developed a custom rubric; the organization calibrated the model, integrated through APIs, and expanded gradually so staff could respond to findings.
Published result: Review expanded from a small weekly sample to a much larger weekly volume, with targeted provider support and template improvements.
Important qualification: Rula continued manually checking a small regular sample to monitor accuracy.
Critical evaluation: Claims of equal or better reliability than humans lack a published agreement statistic, blinded comparison, sensitivity/specificity results, or payer-outcome analysis. No implementation duration or financial ROI is supplied.

This story provides comparatively detailed implementation information and demonstrates that comprehensive AI screening can coexist with ongoing human assurance.

- **Starting problem:** Manual sampling and reviewer inconsistency limited visibility into note quality. - **Implementation:** Clinicians developed a custom rubric; the organization calibrated the model, integrated through APIs, and expanded gradually so staff could respond to findings. - **Published result:** Review expanded from a small weekly sample to a much larger weekly volume, with targeted provider support and template improvements. - **Important qualification:** Rula continued manually checking a small regular sample to monitor accuracy. - **Critical evaluation:** Claims of equal or better reliability than humans lack a published agreement statistic, blinded comparison, sensitivity/specificity results, or payer-outcome analysis. No implementation duration or financial ROI is supplied. This story provides comparatively detailed implementation information and demonstrates that comprehensive AI screening can coexist with ongoing human assurance.

Mixed or unsuccessful experiences

Anonymous reports of poor flags, rejected economics, and difficulty with larger-company suitability provide counterpoints. No detailed, named failed implementation was found. Absence of a public failure case is not evidence that deployments never fail.

Verification of headline metrics

Claim	Assessment
Every chart audited	Coverage claim; does not establish every error is caught or every data source ingested.
Nearly $2 billion protected	Vendor-reported large aggregate value; methodology does not establish actual avoided recoupments or incremental cash recovered.
98% lower review costs / 13× faster reviews	Vendor claims of substantially lower costs and much faster reviews without a disclosed cohort, accounting basis, or independent benchmark.
Zero documentation-related clawbacks on certified charts	Vendor claim without public denominator, observation period, or independent claims reconciliation.
99.2% Headspace compliance	Customer-specific very high compliance result, not system-wide accuracy.

These metrics should be treated as diligence hypotheses rather than transferable forecasts.

| Claim | Assessment | |---|---| | Every chart audited | Coverage claim; does not establish every error is caught or every data source ingested. | | Nearly $2 billion protected | Vendor-reported large aggregate value; methodology does not establish actual avoided recoupments or incremental cash recovered. | | 98% lower review costs / 13× faster reviews | Vendor claims of substantially lower costs and much faster reviews without a disclosed cohort, accounting basis, or independent benchmark. | | Zero documentation-related clawbacks on certified charts | Vendor claim without public denominator, observation period, or independent claims reconciliation. | | 99.2% Headspace compliance | Customer-specific very high compliance result, not system-wide accuracy. | These metrics should be treated as diligence hypotheses rather than transferable forecasts.

04Best fit

The following qualification bands are analyst screening heuristics, not verified vendor eligibility limits.

Screening size range: Small-to-mid-sized organizations up through larger enterprises, or smaller high-volume provider networks with dedicated quality/compliance ownership. Accessible reviews span small, mid, and larger organizations; size alone is not determinative.
Revenue: No evidence-based revenue or ARR range can be assigned. Chart volume, audit labor, reimbursement exposure, and available budget are better qualification variables.
Most clearly represented verticals: Mental health, behavioral health, and ABA. Named vendor stories include Headspace, Rula, and Lightfully.
Decision makers: Medical director, clinical-quality leader, compliance leader, COO, CFO, or revenue-cycle executive.
End users: QA reviewers, clinical supervisors, documentation specialists, and providers responding to findings. These personas align with the reviewed customer roles and workflows.
Potentially suitable characteristics: Written audit standards; a supported data-access path; substantial unscreened documentation; clinical staff available for calibration; and capacity to act on alerts.
Potentially unsuitable characteristics: Low chart volume, unclear ownership of corrections, inability to validate the model, unsupported data requirements, or a need primarily for a scribe rather than an auditor.

The fit judgments follow from the implementation and non-purchase evidence, not from a validated predictive buyer model.

The following qualification bands are analyst screening heuristics, not verified vendor eligibility limits. - **Screening size range:** Small-to-mid-sized organizations up through larger enterprises, or smaller high-volume provider networks with dedicated quality/compliance ownership. Accessible reviews span small, mid, and larger organizations; size alone is not determinative. - **Revenue:** No evidence-based revenue or ARR range can be assigned. Chart volume, audit labor, reimbursement exposure, and available budget are better qualification variables. - **Most clearly represented verticals:** Mental health, behavioral health, and ABA. Named vendor stories include Headspace, Rula, and Lightfully. - **Decision makers:** Medical director, clinical-quality leader, compliance leader, COO, CFO, or revenue-cycle executive. - **End users:** QA reviewers, clinical supervisors, documentation specialists, and providers responding to findings. These personas align with the reviewed customer roles and workflows. - **Potentially suitable characteristics:** Written audit standards; a supported data-access path; substantial unscreened documentation; clinical staff available for calibration; and capacity to act on alerts. - **Potentially unsuitable characteristics:** Low chart volume, unclear ownership of corrections, inability to validate the model, unsupported data requirements, or a need primarily for a scribe rather than an auditor. The fit judgments follow from the implementation and non-purchase evidence, not from a validated predictive buyer model.

The fit judgments follow from the implementation and non-purchase evidence, not from a validated predictive buyer model.

Key Differentiator

05The pitch

—

Get a comprehensive analysis of Brellium including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →